Im not sure much has really changed apart from specific clarification of rux being the 'particular drug that must be trialled and failed, intolerant or contraindicated from the preferred drug list'. As described in the previous note from mid dec.
but for the word rux to now be specifically listed suggests there may have been some strong conversations happening. Is positioning more whats being negotiated than pricing. I think i remember seeing a price for oral rux that was around $150k/yr for one particlar indication. Memory could be off on that.
the other part of note describes some sort of challenge on the historical use of 100 day diagnosis window to distinguish between acute and chronic gvhd.
it seems we may now be having to educate the insurers. Like we did the fda.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)